Please login to the form below

Recordati

This page shows the latest Recordati news and features for those working in and with pharma, biotech and healthcare.

23rd PMEA celebrate excellence in pharmaceutical marketing

The Award for Patient-Centricity went to Recordati Rare Diseases for its entry titled #THISCUSHING – Global Awareness Campaign, Cushing Syndrome, which the panel said “succeeded in bringing emotion into an area

Latest news

New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease

Recordati Rare Disease has revealed new data from a phase 3 trial of its Cushing’s disease treatment Isturisa. ... The normalisation of mUFC levels represents an ‘important’ treatment goal, Recordati said in a statement, by potentially reducing
FDA approves Recordati’s Cushing disease drug Isturisa

Recordati is expecting peak sales of Isturisa of more than $100m a year, according to chief executive Andrea Recordati. ... Patent protection extends to 2031 for Isturisa and 2026 for Signifor LAR, according to Recordati, which had total revenues of
CHMP backs Sanofi’s all-oral sleeping sickness drug

Italy’s Recordati also got a positive opinion for Silodosin Recordati (siloosin) a generic of its own Urorec drug used to treat benign prostatic hyperplasia (BPH).
Daily Brief: Lundbeck gets new leader, Recordati sold, GSK-backed firm prepares for market

Current CEO Andrea Recordati will remain at the helm, and welcomed the deal. ... CVC will aim to expand Recordati’s revenues, including its rare disease business.
Grünenthal buys Zomig rights as AZ slimming drive continues

This work has seen it agree deals with TerSera Therapeutics ($320m for Zoladex), ProStakan ($70m for Moventig), Aspen ($770m for seven anaesthetics drugs) and, most recently, Recordati ($300m for two blood

More from news
Approximately 5 fully matching, plus 20 partially matching documents found.

Latest Intelligence

The good, the bad and the ugly

AstraZeneca, Takeda, Astellas Pharma, Novo Nordisk and Recordati take up the final five positions, though only two - Takeda (3.9%) and Astellas (9.3%) - recorded growth.
Deal Watch July 2016

BioD. $21.3 plus $56.5 contingent. $22m. 3.5x. N/A. Recordati. Pro Farma. ... Recordati has been busy on the acquisition front recently; in May the company acquired Italichimici for $145m, strengthening its gastroenterology and respiratory ranges, and
Deal Watch table for February 2014

4. ). 63. Apricus Biosciences (formerly NexMed) / Recordati. Licence. Vitaros topical treatment for erectile dysfunction.
Deal Watch table for September 2013

246. Laboratorios Casen Fleet/ Recordati. Acquisition. Spanish pharmaceutical company. 123. Pacific Biosciences of California/Roche Diagnostics.
Deal Watch table for July 2013

50. Opalia Pharma / Recordati . Acquisition of 90% stake. Branded generic drugs - dermatology, GI, respiratory.

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

Recordati promotes Andrea Recordati to COO

Milan-based pharmaceutical company Recordati has promoted Andrea Recordati (pictured right) to chief operating officer. ... In his newly-created position, Andrea Recordati will be responsible for all the group's commercial and production activities.